Literature DB >> 19159622

The apolipoprotein A5 -1131T>C promoter polymorphism in Koreans: association with plasma APOA5 and serum triglyceride concentrations, LDL particle size and coronary artery disease.

Yangsoo Jang1, Jean Kyung Paik, Yae Jung Hyun, Jey Sook Chae, Ji Young Kim, Ju Ree Choi, Sang Hak Lee, Dong-Jik Shin, Jose M Ordovas, Jong Ho Lee.   

Abstract

BACKGROUND: The association between -1131T>C single nucleotide polymorphism (SNP) of the apolipoprotein A5 gene (APOA5) and hypertriglyceridemia raised the possibility that this SNP could be related to coronary artery disease (CAD) risk. Therefore, we investigated the association of this APOA5 -1131T>C SNP with circulating concentrations of APOA5, triglyceride and CAD in Koreans.
METHODS: CAD patients (n=741) and age-, sex-matched healthy controls (n=741) were genotyped for the APOA5 -1131T>C SNP. The main outcome measures were the odds ratio (OR) on CAD risk and lipid variables, APOA5 concentration and LDL particle size.
RESULTS: The presence of the minor allele at the -1131T>C SNP was associated with an increased risk of CAD [OR 1.34 (95% CI, 1.09-1.65), P=0.007] after adjusting for BMI, alcohol consumption, systolic blood pressure and diastolic blood pressure. There was an association between the APOA5 concentration and the -1131T>C genotype in controls (T/T: 245+/-7 ng/ml, T/C: 220+/-6, C/C: 195+/-12; P=0.001) and CAD patients (T/T: 218+/-8 ng/ml, T/C: 185+/-7, C/C: 169+/-12; P<0.001). Subjects with T/C or C/C in control and CAD patient groups showed higher triglyceride than those with T/T genotype. Also, the -1131T>C polymorphism was associated with LDL particle size (P=0.003), with the T/C or C/C controls having smaller size than the T/T controls.
CONCLUSIONS: The APOA5 -1131C allele is associated with reduced APOA5 concentration and with increased CAD risk. This is consistent with the observed association between the -1131C SNP, increased triglycerides as well as small LDL particle size.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19159622      PMCID: PMC4428346          DOI: 10.1016/j.cca.2008.12.024

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  29 in total

1.  The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II.

Authors:  P J Talmud; J A Cooper; H Hattori; I P Miller; G J Miller; S E Humphries
Journal:  Diabetologia       Date:  2006-08-18       Impact factor: 10.122

2.  Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren.

Authors:  Kazue Endo; Hisako Yanagi; Jungo Araki; Chiaki Hirano; Kimiko Yamakawa-Kobayashi; Shigeo Tomura
Journal:  Hum Genet       Date:  2002-09-11       Impact factor: 4.132

3.  Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration.

Authors:  H N van der Vliet; M G Sammels; A C Leegwater; J H Levels; P H Reitsma; W Boers; R A Chamuleau
Journal:  J Biol Chem       Date:  2001-09-27       Impact factor: 5.157

4.  Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).

Authors:  Juha Vakkilainen; George Steiner; Jean-Claude Ansquer; Francois Aubin; Stephanie Rattier; Christelle Foucher; Anders Hamsten; Marja-Riitta Taskinen
Journal:  Circulation       Date:  2003-03-24       Impact factor: 29.690

5.  Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.

Authors:  Robert S Rosenson; James D Otvos; David S Freedman
Journal:  Am J Cardiol       Date:  2002-07-15       Impact factor: 2.778

6.  Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

Authors:  J E Hokanson; M A Austin
Journal:  J Cardiovasc Risk       Date:  1996-04

7.  Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease.

Authors:  Csaba Szalai; Márton Keszei; Jenõ Duba; Zoltán Prohászka; Gergely Tibor Kozma; Albert Császár; Sándor Balogh; Zsuzsa Almássy; George Fust; Antal Czinner
Journal:  Atherosclerosis       Date:  2004-03       Impact factor: 5.162

8.  ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis.

Authors:  Frank G Schaap; Patrick C N Rensen; Peter J Voshol; Carlos Vrins; Hendrik N van der Vliet; Robert A F M Chamuleau; Louis M Havekes; Albert K Groen; Ko Willems van Dijk
Journal:  J Biol Chem       Date:  2004-04-16       Impact factor: 5.157

9.  APOA5 gene polymorphism modulates levels of triglyceride, HDL cholesterol and FERHDL but is not a risk factor for coronary artery disease.

Authors:  Kenny W J Lee; Amir F Ayyobi; Jiri J Frohlich; John S Hill
Journal:  Atherosclerosis       Date:  2004-09       Impact factor: 5.162

10.  A single nucleotide polymorphism -1131T>C in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and alters triglyceride metabolism in Chinese.

Authors:  Nan Bi; Sheng-kai Yan; Guo-ping Li; Zhi-nong Yin; Bao-sheng Chen
Journal:  Mol Genet Metab       Date:  2004-11       Impact factor: 4.797

View more
  22 in total

1.  APOA5 gene variation interacts with dietary fat intake to modulate obesity and circulating triglycerides in a Mediterranean population.

Authors:  Carmen Sánchez-Moreno; Jose M Ordovás; Caren E Smith; Juan C Baraza; Yu-Chi Lee; Marta Garaulet
Journal:  J Nutr       Date:  2011-01-05       Impact factor: 4.798

2.  Apolipoprotein A5-1131T>C polymorphism, but not APOE genotypes, increases susceptibility for dyslipidemia in children and adolescents.

Authors:  D D V Brito; A P Fernandes; K B Gomes; F F Coelho; N G Cruz; A P Sabino; J E Cardoso; P P Figueiredo-Filho; R Diamante; C R Norton; M O Sousa
Journal:  Mol Biol Rep       Date:  2010-12-04       Impact factor: 2.316

Review 3.  Adaptive genetic variation and heart disease risk.

Authors:  Laurence D Parnell; Yu-Chi Lee; Chao-Qiang Lai
Journal:  Curr Opin Lipidol       Date:  2010-04       Impact factor: 4.776

4.  Interactions between the APOA5 -1131T>C and the FEN1 10154G>T polymorphisms on ω6 polyunsaturated fatty acids in serum phospholipids and coronary artery disease.

Authors:  Ju Yeon Park; Jean Kyung Paik; Oh Yoen Kim; Jey Sook Chae; Yangsoo Jang; Jong Ho Lee
Journal:  J Lipid Res       Date:  2010-08-27       Impact factor: 5.922

5.  -1131T>C and SW19 polymorphisms in APOA5 gene and lipid levels in type 2 diabetic patients.

Authors:  Mirelle O Sóter; Karina B Gomes; Ana P Fernandes; Maria das G Carvalho; Poliana S Pinheiro; Adriana A Bosco; Daniel D R Silva; Marinez O Sousa
Journal:  Mol Biol Rep       Date:  2012-02-19       Impact factor: 2.316

6.  Apolipoprotein A5 polymorphisms in Turkish population: association with serum lipid profile and risk of ischemic stroke.

Authors:  Birsen Can Demirdöğen; Esra Şahin; Aysun Türkanoğlu Özçelik; Semai Bek; Şeref Demirkaya; Orhan Adali
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

7.  Association of the apolipoprotein A5 gene -1131 T>C polymorphism with fasting blood lipids: a meta-analysis in 37859 subjects.

Authors:  Tongfeng Zhao; Jiangpei Zhao
Journal:  BMC Med Genet       Date:  2010-08-10       Impact factor: 2.103

8.  Association of APOA5 T1131C polymorphism and risk of coronary artery disease.

Authors:  Jing Xia; Weiping Cai; Caosheng Peng
Journal:  Int J Clin Exp Med       Date:  2015-06-15

9.  Apolipoprotein polymorphism is associated with pro-thrombotic profile in non-demented dyslipidemic subjects.

Authors:  Cláudia N Ferreira; Maria G Carvalho; Karina B Gomes; Helton J Reis; Ana-Paula Fernandes; András Palotás; Marinez O Sousa
Journal:  Exp Biol Med (Maywood)       Date:  2014-07-29

10.  Effects of APOA5 -1131T>C (rs662799) on fasting plasma lipids and risk of metabolic syndrome: evidence from a case-control study in China and a meta-analysis.

Authors:  Chunxiao Xu; Rongpan Bai; Dandan Zhang; Zhenli Li; Honghong Zhu; Maode Lai; Yimin Zhu
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.